Artwork

Content provided by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Future-gazing radioligand therapy in prostate cancer | With Oliver Sartor and Michael Hofman

37:27
 
Share
 

Manage episode 464569293 series 3350113
Content provided by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

Look who popped into the GU Cast studio this week for a chat about where we are going next with radioligand therapy (RLT) for prostate cancer! Professors Oliver Sartor (Mayo Clinic, Rochester) and Michael Hofman (Peter Mac, Melbourne), are two of the world's most pre-eminent experts in the world of RLT for prostate cancer. They were each respectively PIs on the VISION and TheraP RCTs published in NEJM and Lancet in 2021, and both have many ongoing trials in RLT for prostate cancer.
We hear in which stages of prostate cancer LuPSMA is next likely to be approved, and some discussion about exciting trials soon to read out. We also discuss other RLTs including actinium and terbium, combinations, imaging technology for patient selection, AI, and the word "cure" even gets a mention. A very entertaining and exciting discussion with two of the best in the business.
Your regular hosts are Professor Declan Murphy and Dr Renu Eapen, Urologists at Peter MacCallum Cancer Centre, Melbourne.
This is a Themed Podcast supported by our Silver Partners, Novartis.

Even better on our YouTube channel
Links:
Michael's paper in the Journal of Nuclear Medicine:"The Hierarchy of SUVs: From Diagnostics to Therapeutics and the Pathway to Effective Theranostics"

  continue reading

181 episodes

Artwork
iconShare
 
Manage episode 464569293 series 3350113
Content provided by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

Look who popped into the GU Cast studio this week for a chat about where we are going next with radioligand therapy (RLT) for prostate cancer! Professors Oliver Sartor (Mayo Clinic, Rochester) and Michael Hofman (Peter Mac, Melbourne), are two of the world's most pre-eminent experts in the world of RLT for prostate cancer. They were each respectively PIs on the VISION and TheraP RCTs published in NEJM and Lancet in 2021, and both have many ongoing trials in RLT for prostate cancer.
We hear in which stages of prostate cancer LuPSMA is next likely to be approved, and some discussion about exciting trials soon to read out. We also discuss other RLTs including actinium and terbium, combinations, imaging technology for patient selection, AI, and the word "cure" even gets a mention. A very entertaining and exciting discussion with two of the best in the business.
Your regular hosts are Professor Declan Murphy and Dr Renu Eapen, Urologists at Peter MacCallum Cancer Centre, Melbourne.
This is a Themed Podcast supported by our Silver Partners, Novartis.

Even better on our YouTube channel
Links:
Michael's paper in the Journal of Nuclear Medicine:"The Hierarchy of SUVs: From Diagnostics to Therapeutics and the Pathway to Effective Theranostics"

  continue reading

181 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Listen to this show while you explore
Play